JP2016510728A5 - - Google Patents

Info

Publication number

JP2016510728A5

JP2016510728A5 JP2015559495A JP2015559495A JP2016510728A5 JP 2016510728 A5 JP2016510728 A5 JP 2016510728A5 JP 2015559495 A JP2015559495 A JP 2015559495A JP 2015559495 A JP2015559495 A JP 2015559495A JP 2016510728 A5 JP2016510728 A5 JP 2016510728A5

Authority

JP

Japan

Prior art keywords

xaa

ophthalmic composition

composition according

topical ophthalmic

pharmaceutical topical

Prior art date

2014-02-27

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 230000000699 topical effect Effects 0.000 claims 17
• 239000000203 mixture Substances 0.000 claims 15
• 235000001014 amino acid Nutrition 0.000 claims 10
• 150000001413 amino acids Chemical class 0.000 claims 10
• 108090000765 processed proteins & peptides Proteins 0.000 claims 7
• 206010012689 Diabetic retinopathy Diseases 0.000 claims 4
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 3
• 230000004770 neurodegeneration Effects 0.000 claims 3
• 208000015122 neurodegenerative disease Diseases 0.000 claims 3
• 230000002207 retinal effect Effects 0.000 claims 3
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
• 239000004472 Lysine Substances 0.000 claims 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
• 235000004279 alanine Nutrition 0.000 claims 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
• 239000004474 valine Substances 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 claims 1
• 208000010412 Glaucoma Diseases 0.000 claims 1
• 101800000224 Glucagon-like peptide 1 Proteins 0.000 claims 1
• DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 1
• 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims 1
• 239000004471 Glycine Substances 0.000 claims 1
• 101500028773 Homo sapiens Glucagon-like peptide 1(7-37) Proteins 0.000 claims 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
• 125000000729 N-terminal amino-acid group Chemical group 0.000 claims 1
• 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
• 206010064930 age-related macular degeneration Diseases 0.000 claims 1
• 125000003277 amino group Chemical group 0.000 claims 1
• 239000006071 cream Substances 0.000 claims 1
• 239000000839 emulsion Substances 0.000 claims 1
• 125000002642 gamma-glutamyl group Chemical group 0.000 claims 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
• 239000006210 lotion Substances 0.000 claims 1
• 208000002780 macular degeneration Diseases 0.000 claims 1
• 210000004897 n-terminal region Anatomy 0.000 claims 1
• 239000002674 ointment Substances 0.000 claims 1
• 239000002997 ophthalmic solution Substances 0.000 claims 1
• 229940054534 ophthalmic solution Drugs 0.000 claims 1
• 230000002265 prevention Effects 0.000 claims 1
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
• 239000000243 solution Substances 0.000 claims 1
• 125000001424 substituent group Chemical group 0.000 claims 1
• 239000000725 suspension Substances 0.000 claims 1
• -1 α -hexadecanoyl Chemical group 0.000 claims 1